參考文獻/References:
[1] Roschewski M, Staudt L M, Wilson W H.Diffuse large B-cell lymphoma-treatment approaches in the molecular era[J].Nat Rev Clin Oncol, 2014, 11(1): 12-23.[2] Polyatskin I L, Artemyeva A S, Krivolapov Y A.Revised WHO classification of tumors of hematopoietic and lymphoid tissues, 2017(4th edition): lymphoid tumors[J].Arkh Patol, 2019, 81(3):59-65.[3] 馬亞輝, 楊琪, 朱洪波, 等.C反應(yīng)蛋白與前白蛋白比值在評估胃癌病人預(yù)后中的臨床價值[J].蚌埠醫(yī)學(xué)院學(xué)報, 2021, 46(2): 214-217, 221.[4] 謝錦華, 吉浩明, 陳國棟,等.小細(xì)胞肺癌患者血清鐵蛋白、紅細(xì)胞沉降率和紅細(xì)胞平均指數(shù)水平與預(yù)后的關(guān)系[J].國際腫瘤學(xué)雜志,2018, 45(8): 465-469.[5] 邵春青,呂虹,劉志偉,等.原發(fā)中樞神經(jīng)系統(tǒng)彌漫性大B細(xì)胞淋巴瘤患者血清細(xì)胞因子白細(xì)胞介素6、白細(xì)胞介素8、白細(xì)胞介素2受體和腫瘤壞死因子α的水平及臨床價值[J].中國臨床醫(yī)生雜志, 2017, 45(8): 57-59.[6] 楊艷.彌漫性大B細(xì)胞淋巴瘤中hENT1、NF-κB的表達及意義[D].安徽:安徽醫(yī)科大學(xué), 2013.[7] 孟偉.TNF-α、TNF-β和PKC-β Ⅱ在彌漫性大B細(xì)胞淋巴瘤中的表達及其意義[D].新疆: 新疆醫(yī)科大學(xué), 2010.[8] 解金洪, 章勻, 唐艷芬.血沉和血清促紅細(xì)胞生成素評估老年慢性阻塞性肺疾病病情和預(yù)后的價值[J].中華保健醫(yī)學(xué)雜志, 2020, 22(6): 638-639, 646.[9] 于洋, 韓春生, 韓桂玲, 等.特發(fā)性肺纖維化患者相關(guān)預(yù)后影響因素的臨床研究[J].世界中醫(yī)藥, 2014, 9(8): 978-982.[10] Liu S, Ren J, Xia Q, et al.Preliminary case-control study to evaluate diagnostic values of C-reactive protein and erythrocyte sedimentation rate in differentiating active Crohn's disease from intestinal lymphoma, intestinal tuberculosis and Behcet's syndrome[J].Am J Med Sci, 2013, 346(6): 467-472.[11] Wu S, Zhou Y, Hua H Y, et al.Inflammation marker ESR is effective in predicting outcome of diffuse large B-cell lymphoma[J].BMC Cancer, 2018, 18(1): 997.[12] Rotaru I, Gaman G D, Stanescu C, et al.Evaluation of parameters with potential prognosis impact in patients with primary gastric diffuse large B cell lymphoma(PG-DLBCL)[J].Rom J Morphol Embryol, 2014, 55(1): 15-21.